Fastinov
2 known investors
FASTinov develops phenotypic Antimicrobial Susceptibility Testing (AST) kits that deliver results within 2 hours directly from blood cultures, covering gram negative and gram positive panels. Its CE-marked in vitro diagnostic products serve clinical laboratories in the European Union.
Investors · 2
Competitors · 4
by search overlap
BioMérieux6 shared keywordsbioMérieux develops in vitro diagnostic solutions for clinical laboratories and healthcare professionals, covering areas such as antimicrobial stewardship, sepsis, and infectious disease detection. It also provides diagnostics for food safety and quality and pharmaceutical quality control.
Affinity Biosensors4 shared keywordsAffinityBio develops LifeScale, a diagnostic system that uses population-profiling technology to identify Gram-negative bacteria in positive blood cultures and perform antibiotic susceptibility testing in roughly 4.5 hours. The system automates sample inoculation, incubation, reading, and reporting for clinical microbiology labs.
iFAST3 shared keywordsiFAST Diagnostics develops a rapid antimicrobial susceptibility testing (AST) system that uses a microfluidic impedance chip to measure the electrical properties of individual bacteria, delivering resistant/susceptible and MIC results from Gram-negative blood cultures or bacterial isolates in under three hours. The technology is aimed at hospital clinical microbiology labs and clinicians to guide antibiotic prescribing and combat antimicrobial resistance, with a focus on the UK market.
Oup3 shared keywordsOxford University Press publishes research, educational, and reference materials, including reports on reading and children's learning, and reference resources such as its dictionary "Word of the Day." It serves readers, educators, and learners across a wide range of subjects worldwide.
Companies competing with Fastinov for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Fastinov do?
- FASTinov develops phenotypic Antimicrobial Susceptibility Testing (AST) kits that deliver results within 2 hours directly from blood cultures, covering gram negative and gram positive panels. Its CE-marked in vitro diagnostic products serve clinical laboratories in the European Union.
- Who are Fastinov's investors?
- Fastinov's investors include Armilar Venture Partners, Bynd Venture Capital.